Terms: = Prostate cancer AND ETV4, PEA3, 2118, ENSG00000175832, E1AF, E1A-F, PEAS3
83 results:
1. Clinical consequences of a genetic predisposition toward higher benign prostate-specific antigen levels.
Shi M; Shelley JP; Schaffer KR; Tosoian JJ; Bagheri M; Witte JS; Kachuri L; Mosley JD
EBioMedicine; 2023 Nov; 97():104838. PubMed ID: 37865044
[TBL] [Abstract] [Full Text] [Related]
2. etv4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer.
Li D; Zhan Y; Wang N; Tang F; Lee CJ; Bayshtok G; Moore AR; Wong EWP; Pachai MR; Xie Y; Sher J; Zhao JL; Khudoynazarova M; Gopalan A; Chan J; Khurana E; Shepherd P; Navone NM; Chi P; Chen Y
Sci Adv; 2023 Apr; 9(14):eadc9446. PubMed ID: 37018402
[TBL] [Abstract] [Full Text] [Related]
3. Identification and characterization of novel etv4 splice variants in prostate cancer.
Cosi I; Moccia A; Pescucci C; Munagala U; Di Giorgio S; Sineo I; Conticello SG; Notaro R; De Angioletti M
Sci Rep; 2023 Mar; 13(1):5267. PubMed ID: 37002241
[TBL] [Abstract] [Full Text] [Related]
4. Glycyl-tRNA Synthetase (GARS) Expression Is Associated with prostate cancer Progression and Its Inhibition Decreases Migration, and Invasion In Vitro.
Khosh Kish E; Gamallat Y; Choudhry M; Ghosh S; Seyedi S; Bismar TA
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901698
[TBL] [Abstract] [Full Text] [Related]
5. Financial Toxicities Persist for cancer Survivors Irrespective of Current cancer Status: An Analysis of Medical Expenditure Panel Survey.
Karim MA; Talluri R; Shastri SS; Kum HC; Shete S
Cancer Res Commun; 2022 Oct; 2(10):1119-1128. PubMed ID: 36531523
[TBL] [Abstract] [Full Text] [Related]
6. Transcriptomes of prostate cancer with TMPRSS2:ERG and Other ETS Fusions.
Stopsack KH; Su XA; Vaselkiv JB; Graff RE; Ebot EM; Pettersson A; Lis RT; Fiorentino M; Loda M; Penney KL; Lotan TL; Mucci LA
Mol Cancer Res; 2023 Jan; 21(1):14-23. PubMed ID: 36125519
[TBL] [Abstract] [Full Text] [Related]
7. Identification of fusions with potential clinical significance in melanoma.
Moran JMT; Le LP; Nardi V; Golas J; Farahani AA; Signorelli S; Onozato ML; Foreman RK; Duncan LM; Lawrence DP; Lennerz JK; Dias-Santagata D; Hoang MP
Mod Pathol; 2022 Dec; 35(12):1837-1847. PubMed ID: 35871080
[TBL] [Abstract] [Full Text] [Related]
8. ETS factors in prostate cancer.
Qian C; Li D; Chen Y
Cancer Lett; 2022 Apr; 530():181-189. PubMed ID: 35033589
[TBL] [Abstract] [Full Text] [Related]
9. Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition.
Raspin K; O'Malley DE; Marthick JR; Donovan S; Malley RC; Banks A; Redwig F; Skala M; Dickinson JL; FitzGerald LM
Prostate; 2022 Apr; 82(5):540-550. PubMed ID: 34994974
[TBL] [Abstract] [Full Text] [Related]
10. etv4 promotes late development of prostatic intraepithelial neoplasia and cell proliferation through direct and p53-mediated downregulation of p21.
Cosi I; Pellecchia A; De Lorenzo E; Torre E; Sica M; Nesi G; Notaro R; De Angioletti M
J Hematol Oncol; 2020 Aug; 13(1):112. PubMed ID: 32791988
[TBL] [Abstract] [Full Text] [Related]
11. Dysregulation of cancer genes by recurrent intergenic fusions.
Yun JW; Yang L; Park HY; Lee CW; Cha H; Shin HT; Noh KW; Choi YL; Park WY; Park PJ
Genome Biol; 2020 Jul; 21(1):166. PubMed ID: 32631391
[TBL] [Abstract] [Full Text] [Related]
12. Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA in situ hybridization.
Dedigama-Arachchige P; Carskadon S; Li J; Loveless I; Alhamar M; Peabody JO; Stricker H; Chitale DA; Rogers CG; Menon M; Gupta NS; Bismar TA; Williamson SR; Palanisamy N
Mod Pathol; 2020 Sep; 33(9):1791-1801. PubMed ID: 32238875
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of four next generation sequencing platforms for fusion detection: Oncomine by ThermoFisher, AmpliSeq by illumina, FusionPlex by ArcherDX, and QIAseq by QIAGEN.
Qu X; Yeung C; Coleman I; Nelson PS; Fang M
Cancer Genet; 2020 May; 243():11-18. PubMed ID: 32197218
[TBL] [Abstract] [Full Text] [Related]
14. Oncogenic ETS Factors in prostate cancer.
Nicholas TR; Strittmatter BG; Hollenhorst PC
Adv Exp Med Biol; 2019; 1210():409-436. PubMed ID: 31900919
[TBL] [Abstract] [Full Text] [Related]
15. Genetic, Environmental, and Nuclear Factors Governing Genomic Rearrangements.
Ramanand SG; Mani RS
Adv Exp Med Biol; 2019; 1210():57-66. PubMed ID: 31900904
[TBL] [Abstract] [Full Text] [Related]
16. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and etv4 on whole-mount radical prostatectomy tissue.
Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N
Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209
[TBL] [Abstract] [Full Text] [Related]
17. Pseudogene Associated Recurrent Gene Fusion in prostate cancer.
Chakravarthi BV; Dedigama-Arachchige P; Carskadon S; Sundaram SK; Li J; Wu KH; Chandrashekar DS; Peabody JO; Stricker H; Hwang C; Chitale DA; Williamson SR; Gupta NS; Navone NM; Rogers C; Menon M; Varambally S; Palanisamy N
Neoplasia; 2019 Oct; 21(10):989-1002. PubMed ID: 31446281
[TBL] [Abstract] [Full Text] [Related]
18. Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome.
Segalés L; Juanpere N; Lorenzo M; Albero-González R; Fumadó L; Cecchini L; Bellmunt J; Lloreta-Trull J; Hernández-Llodrà S
Virchows Arch; 2019 Oct; 475(4):457-466. PubMed ID: 31016435
[TBL] [Abstract] [Full Text] [Related]
19. Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network.
Hellwege JN; Stallings S; Torstenson ES; Carroll R; Borthwick KM; Brilliant MH; Crosslin D; Gordon A; Hripcsak G; Jarvik GP; Linneman JG; Devi P; Peissig PL; Sleiman PAM; Hakonarson H; Ritchie MD; Verma SS; Shang N; Denny JC; Roden DM; Velez Edwards DR; Edwards TL
Sci Rep; 2019 Apr; 9(1):6077. PubMed ID: 30988330
[TBL] [Abstract] [Full Text] [Related]
20. Steroid receptor coactivator-1 regulates glioma angiogenesis through polyomavirus enhancer activator 3 signaling.
Zhang Y; Shi W
Biochem Cell Biol; 2019 Aug; 97(4):488-496. PubMed ID: 30532986
[TBL] [Abstract] [Full Text] [Related]
[Next]
